[HTML][HTML] Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment
Immune checkpoint inhibitors (ICIs) targeting PD-L1 and PD-1 have improved survival in a
subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a …
subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a …
Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment
M Reda, W Ngamcherdtrakul… - Nature …, 2022 - mahidol.elsevierpure.com
Immune checkpoint inhibitors (ICIs) targeting PD-L1 and PD-1 have improved survival in a
subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a …
subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a …
Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment
M Reda, W Ngamcherdtrakul, MA Nelson… - Nature …, 2022 - econpapers.repec.org
Immune checkpoint inhibitors (ICIs) targeting PD-L1 and PD-1 have improved survival in a
subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a …
subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a …
Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment
M Reda, W Ngamcherdtrakul… - Nature …, 2022 - pubmed.ncbi.nlm.nih.gov
Immune checkpoint inhibitors (ICIs) targeting PD-L1 and PD-1 have improved survival in a
subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a …
subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a …
Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment.
M Reda, W Ngamcherdtrakul, MA Nelson… - Nature …, 2022 - europepmc.org
Immune checkpoint inhibitors (ICIs) targeting PD-L1 and PD-1 have improved survival in a
subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a …
subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a …
Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment
M Reda, W Ngamcherdtrakul, MA Nelson… - Nature …, 2022 - ideas.repec.org
Immune checkpoint inhibitors (ICIs) targeting PD-L1 and PD-1 have improved survival in a
subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a …
subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a …
Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment
M Reda, W Ngamcherdtrakul… - Nature …, 2022 - ohsu.elsevierpure.com
Immune checkpoint inhibitors (ICIs) targeting PD-L1 and PD-1 have improved survival in a
subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a …
subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a …
Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment
M Reda, W Ngamcherdtrakul… - Nature …, 2022 - ui.adsabs.harvard.edu
Immune checkpoint inhibitors (ICIs) targeting PD-L1 and PD-1 have improved survival in a
subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a …
subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a …
Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment.
M Reda, W Ngamcherdtrakul… - Nature …, 2022 - search.ebscohost.com
Immune checkpoint inhibitors (ICIs) targeting PD-L1 and PD-1 have improved survival in a
subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a …
subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a …
[HTML][HTML] Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment
M Reda, W Ngamcherdtrakul, MA Nelson… - Nature …, 2022 - ncbi.nlm.nih.gov
Immune checkpoint inhibitors (ICIs) targeting PD-L1 and PD-1 have improved survival in a
subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a …
subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a …